Exploratory study to assess facial tolerability after daily application of several concentrations and formulations containing CD5789 in acne subjects

GALDERMA R&D SNC0 个研究点目标入组 60 人开始时间: 2011年2月14日最近更新: 2017年8月21日

试验速览

暂无简介。

•Male or female subject aged from 18 to 35 years old
•The subject has medical diagnosis of moderate to severe acne vulgaris on the face
•The subject has, on the face, at least 20 inflammatory lesions and 30 non-inflammatory lesions
•If female of childbearing potential,she agrees to use a highly effective double-barrier contraception method for the duration of the study and one month after the last product application.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•The subject has severe forms of acne requiring systemic treatment (acne conglobata, acne fulminans) or secondary acne form (chloracne, drug-induced acne, etc.)
•The subject has a known allergy or sensitivity to any of the components of the study products

发起方

GALDERMA R&D SNC